Current Opinion in Immunology最新文献_第4页

Primary angiitis of the central nervous system 中枢神经系统的原发性脉管炎

IF 5.8 2区医学

Current Opinion in Immunology Pub Date : 2026-02-01 Epub Date: 2025-11-20 DOI: 10.1016/j.coi.2025.102691

Sushmitha Meghashyam , Fatema J Serajee , Aviraag V Prakash , Denise Altinok , AHM Mahbubul Huq

{"title":"Primary angiitis of the central nervous system","authors":"Sushmitha Meghashyam , Fatema J Serajee , Aviraag V Prakash , Denise Altinok , AHM Mahbubul Huq","doi":"10.1016/j.coi.2025.102691","DOIUrl":"10.1016/j.coi.2025.102691","url":null,"abstract":"<div><div>Primary central nervous system vasculitis, also known as primary angiitis of CNS (PACNS), is a rare and heterogeneous inflammatory disorder of blood vessels restricted to the central nervous system. The most common presenting symptoms are headache, focal neurological deficits, and altered cognition. Subtypes of PACNS can have different presentations. Diagnosis is challenging due to clinical, imaging, and histopathological heterogeneity, as well as numerous mimics. The goal of diagnostic work-up is to establish that the neurological presentation is due to an underlying vasculitis based on angiographic or histopathologic features and to exclude infection, systemic vasculitis, or other mimics. Treatment is based on anecdotal evidence and consensus, and includes glucocorticoids and cyclophosphamide for induction of remission, as well as mycophenolate mofetil, rituximab, azathioprine, and methotrexate for maintenance therapy. Only two-thirds of the patients achieve a good neurological outcome. A detailed understanding of the etiopathogenesis and heterogeneity will be necessary for developing more effective biomarkers, precision therapies, and improved outcomes.</div></div>","PeriodicalId":11361,"journal":{"name":"Current Opinion in Immunology","volume":"98 ","pages":"Article 102691"},"PeriodicalIF":5.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145569814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

From X-rays to advanced imaging modalities in pulmonary sarcoidosis 从x线到肺结节病的先进成像方式。

IF 5.8 2区医学

Current Opinion in Immunology Pub Date : 2026-02-01 Epub Date: 2025-12-16 DOI: 10.1016/j.coi.2025.102709

Roberta E Ledda, Camilla Roberti, Nicola Sverzellati

引用次数: 0

Complement deficiencies and infections 补体缺乏和感染

IF 5.8 2区医学

Current Opinion in Immunology Pub Date : 2026-02-01 Epub Date: 2025-12-20 DOI: 10.1016/j.coi.2025.102711

Carine El Sissy , Jérémie Rosain , Mathilde Puel , Cécile Gonnin , Véronique Frémeaux-Bacchi

{"title":"Complement deficiencies and infections","authors":"Carine El Sissy , Jérémie Rosain , Mathilde Puel , Cécile Gonnin , Véronique Frémeaux-Bacchi","doi":"10.1016/j.coi.2025.102711","DOIUrl":"10.1016/j.coi.2025.102711","url":null,"abstract":"<div><div>The complement system is a central component of innate immunity, mediating opsonization, chemotaxis, cytolysis, and shaping adaptive responses. Deficiencies in complement proteins, whether inherited or acquired, predispose to severe infections, particularly with encapsulated bacteria such as <em>Neisseria meningitidis</em> and <em>Streptococcus pneumoniae</em>. Although rare, inherited defects affect different pathways and may also present with autoimmune or renal diseases. Diagnosis relies on functional and quantitative assays, especially in patients with early-onset or recurrent infections. Complement inhibition, introduced with eculizumab and expanded to agents targeting C3, Factor B, or Factor D, has transformed the management of complement-mediated disorders but unmasked novel infectious risks, including meningococcal disease and invasive fungal infections.</div><div>This review summarizes clinical and mechanistic aspects of complement deficiencies, infection risks associated with therapeutic blockade, and current diagnostic strategies. It emphasizes the importance of anticipatory care, vaccination, and prophylaxis as new complement-targeted drugs continue to emerge.</div></div>","PeriodicalId":11361,"journal":{"name":"Current Opinion in Immunology","volume":"98 ","pages":"Article 102711"},"PeriodicalIF":5.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145786834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Interferons in Sjogren’s disease: current status and future prospects 干扰素在干燥病中的应用现状及展望

IF 5.8 2区医学

Current Opinion in Immunology Pub Date : 2026-02-01 Epub Date: 2025-12-05 DOI: 10.1016/j.coi.2025.102703

Sylvia Raftopoulou , Athanasios-Dimitrios Bakasis , Clio P Mavragani

{"title":"Interferons in Sjogren’s disease: current status and future prospects","authors":"Sylvia Raftopoulou , Athanasios-Dimitrios Bakasis , Clio P Mavragani","doi":"10.1016/j.coi.2025.102703","DOIUrl":"10.1016/j.coi.2025.102703","url":null,"abstract":"<div><div>Sjögren’s disease (SjD) is a systemic autoimmune disorder marked by chronic immune activation, with a central role attributed to the interferon (IFN) system. The so-called ‘IFN signature’ at both tissue and peripheral levels has long been recognized as a hallmark of SjD, and recent advances have provided a more detailed molecular understanding of this dysregulation. Nevertheless, the aberrant expression and signaling of type I, II, and, more recently, type III IFNs reflect a complex network of interactions between epithelial and immune cells. This crosstalk is multidirectional, temporospatial, and highly dynamic, shaping the heterogeneity of disease activity, clinical course, and patient phenotypes and endotypes.</div><div>Therapeutic targeting of IFN pathways has emerged as a major focus in SjD, with several clinical trials providing valuable insight. While preliminary benefits have been overwhelmingly promising, outcomes remain somewhat variable, influenced by factors such as trial design, patient stratification, disease stage, and underlying immunological endotypes. These challenges underscore the need for refined approaches to harness IFN modulation effectively in clinical practice.</div><div>This review summarizes current knowledge of the three IFN families and their contribution to SjD pathogenesis, while highlighting recent research advancements that underscore their promise as therapeutic targets. By integrating clinical and translational perspectives, we aim to clarify our understanding of the role of IFNs in SjD and provide a framework for future research and therapy development approaches.</div></div>","PeriodicalId":11361,"journal":{"name":"Current Opinion in Immunology","volume":"98 ","pages":"Article 102703"},"PeriodicalIF":5.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145681212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Indole-3-acetic acid from plants and microbes in human health 吲哚-3-乙酸来源于植物和微生物对人体健康的影响

IF 5.8 2区医学

Current Opinion in Immunology Pub Date : 2026-02-01 Epub Date: 2025-10-31 DOI: 10.1016/j.coi.2025.102683

José López-Bucio , Kirán Rubí Jiménez-Vázquez , Esperanza Martínez-Romero

引用次数: 0

The indole-brain connection: neuroimmune mechanisms and therapy 吲哚-脑连接：神经免疫机制和治疗

IF 5.8 2区医学

Current Opinion in Immunology Pub Date : 2026-02-01 Epub Date: 2025-12-12 DOI: 10.1016/j.coi.2025.102708

Meichang Peng , Haitao Sun

引用次数: 0

Salivary gland organoids and the future of modeling autoimmune epithelitis in Sjögren’s disease 唾液腺类器官和Sjögren疾病自身免疫上皮炎模型的未来

IF 5.8 2区医学

Current Opinion in Immunology Pub Date : 2026-02-01 Epub Date: 2025-12-11 DOI: 10.1016/j.coi.2025.102707

Ting Yang , Negaar Goudarzi , Frans G.M Kroese , Xavier Mariette , Sarah Pringle , Gaetane Nocturne

引用次数: 0

Complement-targeting therapies in hemolytic diseases 溶血性疾病的补体靶向治疗

IF 5.8 2区医学

Current Opinion in Immunology Pub Date : 2026-02-01 Epub Date: 2025-10-29 DOI: 10.1016/j.coi.2025.102686

Anna Duval , Julia Roquigny , Véronique Frémeaux-Bacchi

引用次数: 0

Local complement inhibition by selective precision-targeted therapies 选择性精确靶向治疗的局部补体抑制

IF 5.8 2区医学

Current Opinion in Immunology Pub Date : 2026-02-01 Epub Date: 2025-10-29 DOI: 10.1016/j.coi.2025.102687

Haiyu Wang , Daan J van den Brink , Balthasar A Heesters , Paul WHI Parren , Leendert A Trouw

{"title":"Local complement inhibition by selective precision-targeted therapies","authors":"Haiyu Wang , Daan J van den Brink , Balthasar A Heesters , Paul WHI Parren , Leendert A Trouw","doi":"10.1016/j.coi.2025.102687","DOIUrl":"10.1016/j.coi.2025.102687","url":null,"abstract":"<div><div>Excessive complement activation represents a major pathogenic mechanism for a range of serious human diseases. Complement-inhibitory therapeutics have been approved for a number of rare and ultra-rare conditions, with several others in clinical development. The vast majority of these complement-targeted drugs act via systemic inhibition that requires high dosing with associated high cost and, in addition, carries increased risks for developing life-threatening infectious diseases. Local complement inhibition, allowing lower dosing, lower costs, and a better safety profile, therefore, represents an attractive novel strategy. Several approaches to achieve local complement inhibition, including local application and site-specific targeting, are being assessed. This review will primarily focus on the tissue-specific targeting using antibody technologies for approaches both in preclinical and clinical development, and discuss its advantages and limitations. Overall, we see great promise for an upcoming generation of targeted complement inhibitors that enable selective inhibition of complement exclusively at the site of disease.</div></div>","PeriodicalId":11361,"journal":{"name":"Current Opinion in Immunology","volume":"98 ","pages":"Article 102687"},"PeriodicalIF":5.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145384250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Indole sensing in host, microbiota, and pathogen interactions 宿主、微生物群和病原体相互作用中的吲哚感应。

IF 5.8 2区医学

Current Opinion in Immunology Pub Date : 2026-02-01 Epub Date: 2025-12-16 DOI: 10.1016/j.coi.2025.102710

Mehmet Ali Hoskan, Vanessa Sperandio

引用次数: 0